Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sundlof feels industry's NDI pain

This article was originally published in The Tan Sheet

Executive Summary

FDA's Center for Food Safety and Applied Nutrition currently rejects 80 percent of the new dietary ingredient notifications it receives "because industry doesn't really understand what we require," says center Director Stephen Sundlof. The NDI guidance is "still under review ... but we are pressing to get that out and we know that the industry really wants to have that guidance," Sundlof said at the Food and Drug Law Institute's annual conference April 22 in Washington. Supplement industry stakeholders have long said an NDI guidance would be a key incentive for developing new products, and Sundlof said he realizes publishing the guidance "would be really helpful" to industry. The recent switch by Sens. John McCain, R-Ariz., and Byron Dorgan, D-N.D., from sponsoring a bill that would put new burdens on the industry to backing legislation that requires FDA to complete the NDI notification guidance "as soon as possible" also could compel CFSAN's work (1"The Tan Sheet" March 15, 2010)

You may also be interested in...

Hatch Flips Focus To NDI Guidance In McCain Steroid Bill Negotiations

In a bit of legislative jiu-jitsu, congressional dietary supplement champions have redirected Sen. John McCain from sponsoring a bill that would put new burdens on industry to backing a provision that requires FDA publish a guidance stakeholders have been pushing for

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts